Sofinnova Partners has announced the close of its latest flagship fund, Sofinnova Capital XI, at €650m ($750m), greatly exceeding its initial target.
Sofinnova Capital XI will back a new generation of pioneering biopharmaceutical and medical technology companies addressing urgent unmet clinical needs.
In keeping with Sofinnova’s multi-strategy platform model, Capital XI draws on the strength of its experienced team, including partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter and Graziano Seghezzi.
Sofinnova Capital XI attracted strong support from a global base of blue-chip institutional investors — among them sovereign wealth funds, leading pharmaceutical companies, as well as insurance companies, foundations and family offices.
Commitments came from around the world, with a majority of returning LPs and a significant number of new top-tier investors.
This reflects enduring confidence in Sofinnova’s disciplined strategy and long-standing track record.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said: “This fundraising marks a pivotal moment for Sofinnova."
"It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach."
"We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide."
He added: “Achieving this milestone in today’s volatile fundraising environment speaks to the strength of our model and the confidence our investors continue to place in us.”
Sofinnova Capital XI is actively deploying capital, with investments already made in a few portfolio companies.
The fund will continue to support early-stage biotech and medtech ventures across Europe and North America, participating in both initial and follow-on rounds.